Egyptian International Pharmaceutical Industries Company - Laporan Laba Rugi (TTM)

Egyptian International Pharmaceutical Industries Company
EG ˙ CASE ˙ EGS38081C013
Laporan Laba Rugi (TTM)

Laporan Laba Rugi Egyptian International Pharmaceutical Industries Company menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 2,969 2,886 2,901 2,978 3,171 3,409 3,551 3,623 3,648 3,955 4,020 4,463 4,949 5,232 5,742 6,344 7,003 7,591 8,387 8,819
Change (%) -2.81 0.54 2.63 6.48 7.52 4.16 2.04 0.71 8.41 1.64 11.02 10.89 5.71 9.76 10.47 10.39 8.40 10.50 5.15
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1,808 1,675 1,658 1,679 1,796 1,957 2,045 2,059 2,100 2,397 2,388 2,612 2,837 2,983 3,326 3,572 3,895 4,244 4,654 4,969
Change (%) -7.40 -1.00 1.26 7.02 8.94 4.47 0.72 1.95 14.16 -0.37 9.36 8.63 5.16 11.48 7.40 9.06 8.96 9.66 6.76
% of Revenue 60.90 58.03 57.14 56.38 56.66 57.41 57.59 56.85 57.55 60.60 59.40 58.51 57.32 57.02 57.91 56.30 55.63 55.91 55.49 56.34
Gross Operating Profit 1,161 1,211 1,244 1,299 1,374 1,452 1,506 1,563 1,549 1,558 1,632 1,852 2,112 2,248 2,417 2,772 3,107 3,346 3,733 3,850
Change (%) 4.33 2.68 4.45 5.79 5.65 3.73 3.82 -0.92 0.60 4.75 13.43 14.08 6.45 7.49 14.70 12.09 7.70 11.56 3.14
% of Revenue 39.10 41.97 42.86 43.62 43.34 42.59 42.41 43.15 42.45 39.40 40.60 41.49 42.68 42.98 42.09 43.70 44.37 44.09 44.51 43.66
SG&A 535 548 539 543 573 579 619 660 668 718 743 779 805 827 904 960 994 1,395 1,401 1,491
Change (%) 2.33 -1.61 0.80 5.42 1.15 6.97 6.63 1.21 7.44 3.45 4.89 3.32 2.72 9.26 6.17 3.57 40.36 0.46 6.42
% of Revenue 18.02 18.98 18.57 18.24 18.06 16.99 17.45 18.23 18.32 18.16 18.48 17.46 16.27 15.81 15.74 15.13 14.19 18.38 16.71 16.91
R&D 15 21 27 35 32 35 41 43 41 44 42 43 44 43 53 59 61 70 65 68
Change (%) 39.26 30.19 28.59 -9.29 10.30 16.38 6.89 -5.30 6.06 -2.72 1.94 2.18 -2.34 23.21 10.36 3.08 16.28 -8.19 4.38
% of Revenue 0.50 0.72 0.94 1.17 1.00 1.03 1.15 1.20 1.13 1.10 1.06 0.97 0.89 0.83 0.93 0.93 0.87 0.93 0.77 0.77
OpEx 2,435 2,298 2,293 2,308 2,466 2,632 2,762 2,844 2,885 3,293 3,319 3,613 3,926 4,021 4,524 4,896 5,374 6,088 6,444 6,702
Change (%) -5.59 -0.21 0.62 6.85 6.75 4.96 2.93 1.47 14.14 0.79 8.86 8.66 2.41 12.51 8.23 9.77 13.28 5.84 4.01
% of Revenue 81.99 79.65 79.05 77.50 77.76 77.21 77.81 78.49 79.08 83.26 82.56 80.96 79.33 76.85 78.78 77.18 76.75 80.21 76.83 75.99
Operating Income 535 587 608 670 705 777 788 779 763 662 701 850 1,023 1,211 1,219 1,448 1,628 1,503 1,944 2,118
Change (%) 9.86 3.49 10.22 5.22 10.20 1.44 -1.12 -2.06 -13.26 5.90 21.21 20.41 18.35 0.64 18.79 12.48 -7.72 29.37 8.94
% of Revenue 18.01 20.35 20.95 22.50 22.24 22.79 22.19 21.51 20.92 16.74 17.44 19.04 20.67 23.15 21.22 22.82 23.25 19.79 23.17 24.01
Interest Expense -67 -83 -105 -123 -135 -136 -139 -135 -137 -195 -233 -287 -357 -389 -455 -584 -758 -929 -1,124 -1,231
Change (%) 23.26 25.78 17.96 9.73 0.64 1.79 -2.37 1.12 42.74 19.38 22.83 24.61 8.81 17.06 28.42 29.77 22.52 21.05 9.56
% of Revenue -2.27 -2.88 -3.61 -4.14 -4.27 -4.00 -3.91 -3.74 -3.75 -4.94 -5.80 -6.42 -7.21 -7.43 -7.92 -9.21 -10.82 -12.23 -13.40 -13.96
Net Income 488 487 465 461 472 488 494 544 581 643 658 860 869 822 1,237 1,093 1,163 1,096 811 1,137
Change (%) -0.24 -4.43 -0.90 2.35 3.43 1.29 10.02 6.94 10.62 2.30 30.74 1.03 -5.36 50.48 -11.70 6.44 -5.78 -25.99 40.25
% of Revenue 16.43 16.86 16.03 15.47 14.87 14.31 13.91 15.00 15.93 16.26 16.36 19.27 17.56 15.72 21.55 17.22 16.61 14.44 9.67 12.90

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista